Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DOXIL (LIPOSOMAL) vs ELLENCE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Doxorubicin intercalates between DNA base pairs, inhibits topoisomerase II, and generates free radicals, leading to DNA damage and cell death. Liposomal encapsulation prolongs circulation time and alters biodistribution.
ELLENCE (epirubicin) is an anthracycline cytotoxic antibiotic. It intercalates between DNA base pairs, inhibits topoisomerase II activity, and generates free radicals, leading to DNA damage and cell death.
Ovarian cancer after failure of platinum-based chemotherapy,AIDS-related Kaposi sarcoma,Multiple myeloma in combination with bortezomib
Adjuvant therapy in patients with axillary node-positive breast cancer,Treatment of metastatic breast cancer,Off-label: treatment of ovarian cancer, gastric cancer, small cell lung cancer, and soft tissue sarcoma
Doxorubicin HCl liposome injection 20 mg/m2 intravenously over 1 hour every 4 weeks.
60-120 mg/m2 IV bolus or slow infusion on Day 1 every 21-28 days; or 20-30 mg/m2 IV daily for 3 days repeated every 28 days.
Terminal half-life is approximately 30–40 hours, prolonging drug exposure and allowing every-4-week dosing.
Terminal elimination half-life is approximately 20-40 hours (mean ~30 hours). This supports a 3-week dosing interval to allow for recovery from myelosuppression.
Primarily hepatically metabolized by aldo-keto reductases to doxorubicinol (active metabolite); also metabolized by cytochrome P450 (minor) and glycosidases.
Primarily hepatic metabolism via aldoketoreductases and conjugation; also metabolized by glucuronidation and cytochrome P450 (CYP) enzymes, including CYP2B4 and CYP3A4.
Primarily hepatic metabolism and biliary excretion; urinary excretion accounts for <10% of the administered dose as unchanged drug.
Primarily hepatobiliary excretion: ~40-50% of dose excreted as unchanged drug and metabolites in bile and feces. Renal excretion accounts for <10% (mostly as metabolites).
Approximately 90% bound to plasma proteins, primarily albumin.
Approximately 77% bound to plasma proteins, primarily albumin.
Vd approximately 2.8 L/m² (not directly L/kg; low Vd indicates predominant plasma compartment retention).
Mean volume of distribution is 13-34 L/kg (average ~21 L/kg), indicating extensive tissue distribution and binding.
Only intravenous administration; oral bioavailability is negligible.
IV only; oral bioavailability is negligible (<5%) due to extensive first-pass metabolism. Not administered orally.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended in severe renal impairment (Cr Cl <30 m L/min) due to lack of data.
No specific GFR-based dose adjustments required; caution in severe renal impairment (Cr Cl <10 m L/min) with potential increased toxicity.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: not recommended.
Child-Pugh A: reduce dose by 25%; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated or use at 50% reduction with caution.
Safety and efficacy not established in pediatric patients.
75-100 mg/m2 IV on Day 1 of 21-day cycles or 20-30 mg/m2 IV daily for 3 days every 28 days.
No specific dose adjustment recommended, but monitor for increased toxicity (e.g., cardiotoxicity, myelosuppression) due to age-related organ function decline.
No specific dose adjustment; consider increased susceptibility to myelosuppression and cardiotoxicity; monitor left ventricular ejection fraction.
Cardiotoxicity: risk of myocardial damage, including acute left ventricular failure. Myelosuppression: severe, dose-limiting. Hepatic impairment: requires dose reduction. Infusion reactions: may be severe or life-threatening. Must be administered by physician experienced in cancer chemotherapy.
Myocardial toxicity, including potentially fatal congestive heart failure, especially with cumulative doses >900 mg/m²; secondary acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); extravasation leading to severe tissue necrosis; severe myelosuppression.
Cardiotoxicity (cumulative dose-dependent, monitor LVEF), myelosuppression (neutropenia, thrombocytopenia), infusion reactions (premedicate), hand-foot syndrome (palmar-plantar erythrodysesthesia), secondary malignancies, extravasation necrosis, hepatic impairment (dose adjustment), immunosuppression, embryo-fetal toxicity.
Cardiotoxicity (cumulative dose-dependent), myelosuppression, secondary leukemia, extravasation, hepatotoxicity, renal impairment, immunosuppression, tumor lysis syndrome, and fetal harm.
Absolute: history of hypersensitivity to doxorubicin or other anthracyclines. Relative: severe hepatic impairment, severe myelosuppression, pre-existing cardiomyopathy, prior treatment with maximum cumulative doses of anthracyclines (e.g., doxorubicin >550 mg/m², liposomal doxorubicin >900 mg/m²).
Severe hepatic impairment (Child-Pugh class C), severe renal impairment (Cr Cl <30 m L/min), baseline neutrophil count <1500 cells/mm³, severe cardiac dysfunction, hypersensitivity to epirubicin or other anthracyclines.
No specific food interactions reported. Avoid grapefruit juice per general chemotherapy precautions. Maintain adequate oral hygiene; avoid spicy or acidic foods during mucositis.
Avoid grapefruit and grapefruit juice during treatment as they may affect drug metabolism. No other specific food interactions known.
Doxorubicin hydrochloride liposome injection (DOXIL) is classified as Pregnancy Category D. There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans. Potential benefits may warrant use of the drug in pregnant women despite potential risks. First trimester: High risk of teratogenicity including major malformations (e.g., cardiovascular, neural tube defects). Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and neonatal myelosuppression. Use only if clearly needed and no safer alternative.
Pregnancy Category D. First trimester: High risk of teratogenicity including cardiac anomalies, skeletal defects, and fetal demise. Second and third trimesters: Risk of fetal growth restriction, preterm birth, and neonatal myelosuppression. Avoid use unless absolutely necessary.
Doxorubicin is excreted in human milk. The milk-to-plasma (M/P) ratio for doxorubicin is approximately 0.5 to 2.0 based on limited data. Because of the potential for serious adverse reactions in nursing infants from doxorubicin (e.g., myelosuppression, cardiotoxicity), discontinue breastfeeding during and for at least 3 months after the last dose of DOXIL.
Contraindicated due to potential transfer into breast milk (M/P ratio not available). Theoretical risk of severe adverse effects in infants including bone marrow suppression and cardiotoxicity. Discontinue nursing or drug.
Pharmacokinetic data in pregnancy are limited; however, physiological changes (e.g., increased plasma volume, hepatic clearance) may alter doxorubicin exposure. No specific dose adjustment guidelines exist. Use the standard dose based on body surface area (BSA) while closely monitoring for toxicity. Consider dose reduction if severe myelosuppression or hepatic impairment occurs. Avoid use in the first trimester if possible.
No established dose adjustments; avoid use if possible. Pharmacokinetic changes include increased volume of distribution and clearance, but insufficient data to recommend dose modification. Use reduced doses if unavoidable, guided by toxicity monitoring.
Monitor for infusion reactions; premedicate with dexamethasone and antihistamines. Palmar-plantar erythrodysesthesia (hand-foot syndrome) may require dose delay/reduction. Cumulative dose >550 mg/m² increases cardiotoxicity risk. Do not substitute with non-liposomal doxorubicin.
Ellence (epirubicin) is an anthracycline chemotherapeutic agent. It is a vesicant; extravasation can cause severe tissue necrosis. Administer via a freely flowing IV line. Premedicate with antiemetics. Monitor for cardiotoxicity, which is dose-dependent and may be cumulative. Total lifetime dose should not exceed 900-1000 mg/m². Assess cardiac function (LVEF) before and during treatment. Urine may turn red for 1-2 days after administration. Avoid live vaccines.
Report immediately any redness, swelling, or pain on palms or soles (hand-foot syndrome).,Avoid prolonged sun exposure and use sunscreen to prevent photosensitivity.,Notify your doctor if you experience chest pain, shortness of breath, or swelling (cardiotoxicity signs).,Take anti-nausea medications as prescribed; maintain adequate hydration.,Use effective contraception during treatment and for 6 months after.
Ellence can cause severe nausea and vomiting; take antiemetics as prescribed.,Report any pain, redness, or swelling at the injection site immediately.,Urine may appear red for 1-2 days after treatment; this is normal.,Use effective contraception during and for at least 6 months after treatment.,Avoid live vaccines (e.g., MMR, varicella) while on this medication.,Report signs of infection (fever, chills), unusual bleeding or bruising, shortness of breath, or chest pain.,Do not breastfeed while taking Ellence.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DOXIL (LIPOSOMAL) vs ELLENCE, answered by our medical review team.
DOXIL (LIPOSOMAL) is a Anthracycline Antineoplastic that works by Doxorubicin intercalates between DNA base pairs, inhibits topoisomerase II, and generates free radicals, leading to DNA damage and cell death. Liposomal encapsulation prolongs circulation time and alters biodistribution.. ELLENCE is a Anthracycline Antineoplastic that works by ELLENCE (epirubicin) is an anthracycline cytotoxic antibiotic. It intercalates between DNA base pairs, inhibits topoisomerase II activity, and generates free radicals, leading to DNA damage and cell death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DOXIL (LIPOSOMAL) and ELLENCE depend on the specific clinical indication. These are both Anthracycline Antineoplastic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DOXIL (LIPOSOMAL) is: Doxorubicin HCl liposome injection 20 mg/m2 intravenously over 1 hour every 4 weeks.. The standard adult dose of ELLENCE is: 60-120 mg/m2 IV bolus or slow infusion on Day 1 every 21-28 days; or 20-30 mg/m2 IV daily for 3 days repeated every 28 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DOXIL (LIPOSOMAL) and ELLENCE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DOXIL (LIPOSOMAL) is classified as Category C. Doxorubicin hydrochloride liposome injection (DOXIL) is classified as Pregnancy Category D. There is positive evidence of human fetal risk based on adverse reaction data from inves. ELLENCE is classified as Category C. Pregnancy Category D. First trimester: High risk of teratogenicity including cardiac anomalies, skeletal defects, and fetal demise. Second and third trimesters: Risk of fetal growt. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.